These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 21415218

  • 1. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.
    Chiong E, Lee IL, Dadbin A, Sabichi AL, Harris L, Urbauer D, McConkey DJ, Dickstein RJ, Cheng T, Grossman HB.
    Clin Cancer Res; 2011 May 01; 17(9):2863-73. PubMed ID: 21415218
    [Abstract] [Full Text] [Related]

  • 2. In vivo and in vitro effects of RAD001 on bladder cancer.
    Vasconcelos-Nóbrega C, Pinto-Leite R, Arantes-Rodrigues R, Ferreira R, Brochado P, Cardoso ML, Palmeira C, Salvador A, Guedes-Teixeira CI, Colaço A, Palomino LF, Lopes C, Santos L, Oliveira PA.
    Urol Oncol; 2013 Oct 01; 31(7):1212-21. PubMed ID: 22169072
    [Abstract] [Full Text] [Related]

  • 3. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma.
    Imura Y, Yasui H, Outani H, Wakamatsu T, Hamada K, Nakai T, Yamada S, Myoui A, Araki N, Ueda T, Itoh K, Yoshikawa H, Naka N.
    Mol Cancer; 2014 Aug 07; 13():185. PubMed ID: 25098767
    [Abstract] [Full Text] [Related]

  • 4. mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells.
    Cai Y, Xia Q, Su Q, Luo R, Sun Y, Shi Y, Jiang W.
    Int J Mol Med; 2013 Apr 07; 31(4):904-12. PubMed ID: 23426850
    [Abstract] [Full Text] [Related]

  • 5. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.
    Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O.
    Br J Cancer; 2013 Sep 17; 109(6):1586-92. PubMed ID: 23989949
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer.
    Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, Kassouf W.
    Cancer Biol Ther; 2009 Dec 17; 8(24):2339-47. PubMed ID: 20061787
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo.
    Yang J, Ikezoe T, Nishioka C, Ni L, Koeffler HP, Yokoyama A.
    Exp Hematol; 2010 Aug 17; 38(8):666-76. PubMed ID: 20382200
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells.
    Lin JF, Lin YC, Yang SC, Tsai TF, Chen HE, Chou KY, Hwang TI.
    Drug Des Devel Ther; 2016 Aug 17; 10():1501-13. PubMed ID: 27143856
    [Abstract] [Full Text] [Related]

  • 13. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel.
    Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, Wu W, Kitange GJ, Grogan PT, Goble JM, Uhm J, Galanis E, Giannini C, Lane HA, James CD, Sarkaria JN.
    Clin Cancer Res; 2008 Jun 15; 14(12):3993-4001. PubMed ID: 18559622
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma.
    Hirashima K, Baba Y, Watanabe M, Karashima RI, Sato N, Imamura Y, Nagai Y, Hayashi N, Iyama KI, Baba H.
    Br J Cancer; 2012 Feb 28; 106(5):876-82. PubMed ID: 22333597
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer.
    Gee J, Lee IL, Jendiroba D, Fischer SM, Grossman HB, Sabichi AL.
    Oncol Rep; 2006 Feb 28; 15(2):471-7. PubMed ID: 16391871
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.